Medicine for treating Alzheimer's disease and preparation method thereof

Abstract

The invention discloses a medicine for treating Alzheimer's disease and a preparation method thereof. The medicine for treating the Alzheimer's disease is prepared from the following components in parts by mass: 10 to 15 parts of curcumin, 15 to 30 parts of silymarin, 8 to 12 parts of ginkgo biloba extract, 20 to 30 parts of uva ursi extract, 15 to 30 parts of corn stigma extract, 6 to 12 parts of larix gmelini extract, 12 to 16 parts of dandelion extract, 16 to 20 parts of American ginseng extract, 10 to 15 parts of fructus evodiae extract, 10 to 20 parts of polygonum multiflorum extract, 5 to 15 parts of saffron extract, 13 to 17 parts of acanthopanax root extract, 5 to 10 parts of salvia miltiorrhiza extract, 10 to 20 parts of radix puerariae extract, and 20 to 30 parts of gynostemma pentaphylla extract. The medicine has the advantages that the absorbing rate of Chinese herbal medicine prescription is improved, the synergistic function of Chinese herbal medicine prescription in pharmacological effect is realized, the functions of combining positive and evil, invigorating qi and removing blood stasis, tonifying kidney and strengthening brain, improving learning and memory capability and the like are realized, and the therapy effect is obvious.

Description

technical field [0001] The invention relates to the technical field of traditional Chinese medicine compositions, in particular to a medicine for treating senile dementia and a preparation method thereof. Background technique [0002] Alzheimer's disease or senile Alzheimer's disease (Alzheimer's disease, AD) is a common disease of the elderly worldwide, accounting for the fourth cause of human death. It was discovered by Bavarian neuropathologist Alzheimer in 1907. It was first discovered and named after it. AD is a diffuse central neurodegenerative disorder characterized by progressive cognitive impairment, mental decline, and personality changes with senile plaques, brain amyloid Aβ1-42 deposits, neurofibrillary tangles, neuronal loss, and slow inflammatory pathological features. The etiology and pathogenesis of AD are still unclear. There is a large amount of evidence that the accumulation of amyloid Aβ1-42 in brain tissue is the culprit of Alzheimer's disease, but the...

AI Technical Summary

Problems solved by technology

[0005] At present, the drugs for the treatment of AD mainly include: Acetyl cholinesterase inhibitors (AChEIs), NMDA antagonists, other Semagacestat (LY450139), ACC-001, etc. These drugs are effective for temporarily relieving memory impairment, but the curative effects are all mixed. See General, and does not prevent or reverse underlying neurological decline

At present, the human monoclonal antibody developed is mainly to clear the β-amyloid protein in the brain, which can prevent or even reverse the progress of Alzheimer's disease, but it is found to be unsafe after testing and has great side effects

Images